Bayer Logo Bayer Logo Bayer Logo

Kyleena® Dosing and Efficacy

Women want a low-dose birth control option

In an online survey of 1000 women considering hormonal birth control1

50% of women surveyed said they were open to using an IUD and 67% of those women would like to have a low-dose option

The survey conducted by Bayer in September 2019 included women aged 18-44 who were currently taking or considering taking hormonal prescription birth control in the next 12 months.1


IUD=intrauterine device.

Kyleena acts locally and provides low hormone levels

Comparison of simulated typical serum LNG concentrations2*

Graph showing comparison of simulated typical serum LNG concentrations

Low daily release rates3

Table showing Kyleena® (levonorgestrel-releasing intrauterine system) 19.5 mg and Mirena® (levonorgestrel-releasing intrauterine system) 52 mg daily release rates


High contraceptive efficacy maintained over 5 years3

Kyleena is the lowest-dose 5-year IUD3

Yearly and overall 5 year efficacy rate

The efficacy of Kyleena over 5 years was studied in parous and nulliparous women across a broad range of ages and body mass index (BMI).3


  • Ages in the clinical trial subjects ranged from 18 to 35
  • The weight range for Kyleena-treated women was 38 kg to 173 kg (84 lbs to 381 lbs)
  • Mean BMI was 25.3 kg/m2 (range 15.2-57.6 kg/m2)


Year 1: Pearl Index of 0.16; 95% upper CL of 0.58; cumulative 5-year pregnancy rate, based on 13 pregnancies, estimated by the Kaplan-Meier method was 1.45%; 95% upper CL of 2.53%.3

CL=confidence limit.


Request a Rep

Stay up to date with clinical information and virtual trainings for Kyleena.


See how Kyleena impacts bleeding

Know what patients may expect in the first 3 to 6 months and up to 5 years of use.


A non-daily contraception option

Learn more about Kyleena as a non-daily contraception option.